Suneva Medical, a US-based dermatology and aesthetic product developer that counts pharmaceutical company Almirall as an investor, received $25m in funding from growth equity firm Essex Woodlands on Tuesday.
The investment will support commercial activities for two Suneva products: skin repair product Regenica and Bellafill, a dermal filler used to combat acne scarring and smile lines.
Suneva has now raised about $105m in equity funding, including $15m in series C funding from Almirall in July 2015, and $35m in debt financing from Comerica Bank and Healthcare Royalty Partners.
Other Suneva investors include Polaris Partners and HealthCare Royalty. Essex Woodlands will take a seat on Suneva’s board of directors in conjunction with its investment, for which Leerink Partners was placement agent.
Nicholas L. Teti, Jr, chairman and CEO of Suneva Medical, said: “The additional funding from Essex Woodlands fortifies our position and allows us to further accelerate the strong momentum of the business which remains committed to product innovation backed by rigorous scientific data.”